Description du projet
Une biopsie liquide innovante à haute sensibilité pour le traitement du cancer
L’analyse des biomarqueurs du cancer pendant le suivi du traitement et au cours de la période postopératoire exige une sensibilité élevée. Le projet BiopSense, financé par l’UE, développe une nouvelle technologie de détection extrêmement sensible du polymorphisme mononucléotidique dans les échantillons, permettant un dépistage sur le lieu de soin des biopsies liquides. Cette plateforme de diagnostic constituera un système ouvert qui peut se prêter à la conception de nouvelles cibles de diagnostic. La technologie est basée sur une invention brevetée et comprendra des fonctions de préparation automatisée des échantillons et de conception de laboratoire sur puce. Les objectifs du projet consistent notamment à vérifier les composants complets de la plateforme et à établir la sensibilité et la précision de la chimie en vue d’une évaluation par comparaison avec une plateforme de spectrométrie de masse concurrente.
Objectif
Extremely high sensitivity is needed for the detection of cancer biomarkers during the follow-up of the treatment or post-operation period. We have identified a novel technology that enables very sensitive detection of single-nucleotide polymorphism from blood, enabling point-of-care screening of liquid biopsies. Our diagnostics platform will consist of new chemistry and device, and is an open system for designing new diagnostic targets. This will enable customized follow-up of the cancer medication in local hospitals and health care centers. The technology is based on our invention (US patent allowed) further developed in the ERC CoG project, but will have features for automated sample preparation and lab-on-chip design, which need to be verified and combined in the complete platform. For pre-commercialization of the technology, the sensitivity and accuracy of the chemistry will be determined and compared against competing mass spectrometric platform (UltraSEEK by Agena), upgrading our technology from phase TRL 4 to TRL 5. Patent shield of the technology is extended and options for transferring IPR from the University are clarified. Results are presented in investor convention and oncology conferences, and negotiations with investors and out-licensors are started. Three international biotech companies take part in the steering group. The technology allows business potential in device and kit production, but especially in international service business for personalised panel components and medical consultation. The expected price of the device and sample prep will be 30-40% cheaper than that of the closest competitor, but even better it allows flexible design of personalized diagnostic panels. The development for boosting the innovation to market will continue either through a spin-out supported by international investors, together with partnering companies, or through out-licensing.
Champ scientifique
Programme(s)
Régime de financement
ERC-POC - Proof of Concept GrantInstitution d’accueil
40100 Jyvaskyla
Finlande